Cardiovascular risk management in clinical practice: Time to change

High Blood Pressure and Cardiovascular Prevention

Volumn 15, Issue 1, 2008, Pages 9-16

  Volpe, Massimo ^a,b   Erhardt, Leif R W ^c   Williams, Bryan ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cardiovascular diseases; Cardiovascular prevention; Cardiovascular risk; Risk factors

Indexed keywords

ATORVASTATIN;

CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DYSLIPIDEMIA; HEALTH CARE QUALITY; HUMAN; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION;

EID: 43049094427     PISSN: 11209879     EISSN: None     Source Type: Journal    
DOI: 10.2165/00151642-200815010-00003     Document Type: Review

References (67)

1. World Health Organization. Program and projections of the world health organization on cardiovascular diseases [online]. Available from URL: http:// www.who.int/cardiovascular_diseases/en/ [Accessed 2008 Jan 31]
2. Schober SE, Mirel LB, Graubard BI, et al. Blood lead levels and death from all causes, cardiovascular disease, and cancer: results from the NHANES III mortality study. Environ Health Perspect 2006; 114 (10): 1538-41
3. EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European action on secondary prevention through intervention to reduce events [published erratum appears in Eur Heart J 1998; 19 (2): 356-7]. Eur Heart J 1997; 18 (10): 1569-82
4. Grundy SM, Brewer Jr JB, Cleeman JI, et al. American Heart Association, National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Definition of metabolic syndrome. Circulation. 2004; 109 (3): 433-8
5. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355 (25): 2631-9
6. Danaei G, Lawes CM, Vander Hoorn S, et al. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 2006; 368 (9548): 1651-9
7. Abegunde DO, Mathers CD, Adam T, et al. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007; 370 (9603): 1929-38
8. Boersma E, Keil U, De Bacquer D, et al. for the EUROASPIRE I and II Study Groups. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 2003; 21 (10): 1831-40
9. Volpe M, Erhardt LR, Williams B. Managing cardiovascular risk: the need for change. J Hum Hypertens 2008 Feb; 22 (2): 154-7
10. Volpe M, Alderman MH, Furberg CD, et al. Beyond hypertension toward guidelines for cardiovascular risk reduction. Am J Hypertens 2004; 17 (11 Pt 1): 1068-74
11. Alderman MH, Furberg CD, Kostis JB, et al. Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens 2002; 15 (10 Pt 1): 917-23
12. Volpe M, Tocci G. Joined-up cardiovascular risk management for the future: lessons learned from the ASCOT trial. Aging Clin Exp Res 2005; 17 (S4): S46-53
13. Bensing J. Bridging the gap: the separate worlds of evidence-based medicine and patient-centered medicine. Patient Educ Counsel 2000; 39: 17-25
14. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13 (1 Pt 2): 3S-10S
15. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profile. Am Heart J 1991; 121: 293-8
16. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial (MRFIT) Research Group. Arch Intern Med 1992; 152: 56-64
17. Asia Pacific Cohort Studies Collaboration (APCSC). Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation 2005; 112 (22): 3384-90
18. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52
19. Emberson J, Whincup P, Morris R, et al. Evaluating the impact of population and high-risk strategies for the primary prevention of CVD. Eur Heart J 2004; 25: 484-91
20. Patrono C, García Rodríguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353 (22): 2373-83
21. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update - consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106 (3): 388-91
22. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 Suppl. 2: S1-113
23. Chobanian A, Bakris G, Black H, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-71
24. Williams B, Poulter NR, Brown MJ, et al. for the British Hypertension Society (BHS) Guidelines. Guidelines of management of hypertension: report of the fourth working party on British Hypertension Society - BHS IV. J Hum Hypertens 2004; 18: 139-85
25. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105-87
26. Grundy SM, Cleeman JI, Merz CN, et al. for the Coordinating Committee of the National Cholesterol Education Program (NCEP). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39
27. Dahlof B, Devereux RB, Kjeldsen SE, et al. for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension (LIFE) study: a randomised trial against atenolol. Lancet 2002; 359: 995-1003
28. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) randomised trial. Lancet 2004; 363 (9426): 2022-31
29. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-16
30. Dahlof B, Sever PS, Poulter NR, et al. for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895-906
31. Mochizuki S, Dahlof B, Shimizu M, et al. Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369 (9571): 1431-9
32. Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370 (9590): 829-40
33. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, part 1: prolonged differences in blood pressure - prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774
34. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-839
35. Lewington S, Clarke R, Qizilbash N, for the Prospective Studies Collaboration, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13
36. Sheridan S, Pignone M, Mulrow C. Framinghan-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med 2003; 18 (2): 1039-52
37. El Fakiri F, Bruijnzeels MA, Hoes AW. Prevention of cardiovascular diseases: focus on modifiable cardiovascular risk. Heart 2006; 92: 741-5
38. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93
39. Sacks FM, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Evens (CARE) Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
40. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360 (9326): 7-22
41. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomised ontrolled trial. Lancet 2003; 361:1149: 1158
42. Collhoun MH, Betteridge DJ, Durrington PH, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2005; 364: 685-96
43. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78
44. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-45
45. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48 (3): 438-45
46. Sesti G, Volpe M, Cosentino F, et al. Metabolic syndrome: diagnosis and clinical management, an official document of the Working Group of the Italian Society of Cardiovascular Prevention (SIPREC). High Blood Press Cardiovasc Prev 2006; 13 (4): 185-98
47. Elisaf M. The treatment of coronary heart disease: an update, part 1: an overview of the risk factors for cardiovascular disease. Curr Med Res Opin 2001; 17 (1): 18-26
48. Dominguez LJ, Galioto A, Ferlisi A, et al. Ageing, lifestyle modifications, and cardiovascular disease in developing countries. J Nutr Health Aging 2006 Mar-Apr; 10 (2): 143-9
49. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113 (6): 791-8
50. Pearson TA, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67
51. Volpe M, Machado E. Treatment priorities and current prescribing patterns in hypertension: results of Global Research on Attitudes about hypertension and Stroke Prevention (GRASP), an international physician survey. Curr Med Res Opin 2004; 20 (7): 1151-60
52. Erhardt LR, Pearson TA, Bruckert E, et al. Guidelines and their implementation: discussion document focused on the best approaches to drive improvement. Vasc Dis Prev 2004; 1: 167-74
53. Backlund L, Bring J, Strender LE. How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients? Prim Health Care Res Dev 2004; 5: 153-61
54. Grover SA, Lowensteyn I, Esrey KL, et al. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ 1995; 310: 975-8
55. Putnam W, Twohig PL, Burge FI, et al. Evidence-based cardiovascular care: family physicians' views of obstacles and opportunities. Can Fam Physician 2004; 50: 1397-405
56. Backlund L, Skaner Y, Montgomery H, et al. The role of guidelines and the patient's life-style in GPs' management of hypercholesterolaemia. BMC Fam Pract 2004; 5: 3
57. Manuel DG, Lim J, Tanuseputro P, et al. Revisiting Rose: strategies for reducing coronary heart disease. BMJ 2006; 332 (7542): 659-62
58. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program I: reduction in mortality of persons with high blood pressure including mild hypertension. JAMA 1979; 242: 2562-71
59. Tunstal-Pedoe H. The Dundee coronary risk-disk for management of change in risk factors. BMJ 1991; 303: 744-7
60. Voss R, Cullen P, Schulte H, et al. Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Munster Study (PROCAM) using neural networks. Int J Epidemiol 2002; 31: 1253-62
61. Conroy RM, Pyorala K, Fitzgerald AP, et al. for the SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24 (11): 987-1003
62. Giampaoli S, Palmieri L, Chiodini P, et al. Gruppo di Ricerca del Progetto CUORE. The global cardiovascular risk chart. Ital Heart J Suppl 2004; 5 (3): 177-85
63. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139: 272-8
64. Hobbs FDR, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002; 19: 596-604
65. Mancia G, Ambrosioni E, Rosei EA, et al. for the ForLife study group. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens 2005; 23 (8): 1575-81
66. Murray CJ, Lauer JA, Hutubessy RC, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk [published erratum appears in Lancet 2005; 366 (9481): 204]. Lancet 2003; 361 (9359): 717-25
67. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007 Apr; 11 (14): 1-160